CRANBURY, NJ — Solco Healthcare is proud to announce its FDA approval for Telmisartan tablets, 20mg, 40mg and 80mg, which are AB-rated equivalents to Micardis® by Boehringer Ingelheim.

“This recent approval continues to support Solco’s ability to provide high quality, cost effective medications to those in need,” said Hai Wang, President of Solco Healthcare. Telmisartan tablets are used for treating high blood pressure alone or with other medicines. It is also used to reduce the risk of heart attack, stroke, or death due to heart problems in certain patients.  According to QuintilesIMS, total market sales for Telmisartan tablets for the last twelve months ending March 2017 were $73.7 million.

Solco Healthcare will market Telmisartan tablets in 30 count bottles for all three strengths.  Solco anticipates launching these products in the very near future.  Please contact your Solco Healthcare National Accounts Director or customer service at 1-888-869-8008 for more information.